Jiang Huling, Zhou Chiyan, Yang Li, Li Suping, Liu Xiaodan
Prenatal Diagnosis Center, Jiaxing Maternity and Child Health Care Hospital, Jiaxing, Zhejiang 314009, China.
Zhonghua Yi Xue Yi Chuan Xue Za Zhi. 2023 Mar 10;40(3):295-300. doi: 10.3760/cma.j.cn511374-20220121-00054.
To study the molecular epidemiology of thalassemia in Jiaxing area of Zhejiang province and provide a basis for prenatal diagnosis, genetic counseling and prevention and control of birth defects.
A total of 24 003 pregnant women who presented at the Jiaxing Maternal and Child Health Care Hospital from April 2017 to September 2021 were enrolled. Capillary hemoglobin electrophoresis in combination with routine blood test were used for primary screening for carriers of thalassemia-associated mutations, and those with positive results were subjected to fluorescence quantitative PCR assay. Prenatal diagnosis was provided for couples with a risk of giving birth to children with intermediate or severe thalassemia.
Among the 24 003 pregnant women, 1 211 cases were suspected as carriers of thalassemia-associated mutations, among whom 443 (36.58%) were confirmed by genetic testing. Among these, carriers of α-, β- and α-complex β-globin gene mutations have accounted for 27.31% (121/443), 70.65% (313/443) and 2.04% (9/443), respectively. The result of prenatal diagnosis for an at-risk couple was --SEA/αCSα, and the fetus was predicted to have intermediate or severe thalassemia. Termination of the pregnancy was recommended.
Hemoglobin electrophoresis combined with routine blood test during pregnancy may be used as a preliminary screening measure for carriers of thalassemia-associated variants. Combined with genetic testing, this will be of great significance for the control of thalassemia in this region.
研究浙江省嘉兴地区地中海贫血的分子流行病学,为产前诊断、遗传咨询及出生缺陷防控提供依据。
纳入2017年4月至2021年9月在嘉兴市妇幼保健院就诊的24003例孕妇。采用毛细管血红蛋白电泳联合血常规进行地中海贫血相关突变携带者的初筛,初筛阳性者行荧光定量PCR检测。为有生育中间型或重型地中海贫血患儿风险的夫妇提供产前诊断。
240,03例孕妇中,1211例疑似为地中海贫血相关突变携带者,其中443例(36.58%)经基因检测确诊。其中,α-、β-和α复合β珠蛋白基因突变携带者分别占27.31%(121/443)、70.65%(313/443)和2.04%(9/443)。一对高危夫妇的产前诊断结果为--SEA/αCSα,预测胎儿患有中间型或重型地中海贫血。建议终止妊娠。
孕期血红蛋白电泳联合血常规可作为地中海贫血相关变异携带者的初步筛查手段。结合基因检测,对该地区地中海贫血的防控具有重要意义。